Journal of Clinical Oncology Impact Factor 2024: 41.2 | Acceptance Rate & Guide

The Journal of Clinical Oncology is the flagship publication of the American Society of Clinical Oncology (ASCO). With an impact factor of 41.2, it's the highest-IF journal specifically in clinical oncology and publishes the randomized trial results and clinical practice updates that set the standard for cancer treatment globally.

Impact factor trend

JCO's IF has been growing steadily since 2015, reflecting the explosion in clinical trial output in oncology. The slight 2024 dip from the 2022 peak mirrors patterns across high-IF journals as post-pandemic citation patterns normalize. The underlying trend is stable.

What JCO editors are looking for

JCO's editorial standard is specific: does your study change how oncologists treat patients?

Not refine. Not provide additional evidence for a known effect. Change. The bar requires that a practicing oncologist reading your paper would consider doing something differently in clinic.

This standard immediately rules out several common submission types:

Small retrospective series: single-institution reviews of 50-150 patients without a practice-changing conclusion. These belong in specialty journals, not JCO.

Biomarker studies without clinical validation: identifying a prognostic biomarker in a retrospective cohort is not, by itself, a JCO paper. A prospective validation in a clinical trial population is.

Basic science without clinical translation: JCO is a clinical journal. Cell line and animal data belong in Cancer Cell, Cancer Research, or a molecular oncology journal unless directly tied to a clinical dataset.

Confirmatory studies: a third study showing the same effect that two previous studies have already established. Unless you're providing practice-changing subgroup data or a different patient population with different implications, this is incremental.

Acceptance rate and desk rejection

JCO's 15% acceptance rate is higher than most comparable journals, but the headline includes all article types: letters, editorials, commentary, and short communications that go through different review processes.

For primary research articles:

• Desk rejection: ~40% of research submissions
• External review rate: ~30-35%
• Acceptance from those reaching review: ~30-40%

Desk rejections at JCO are predominantly scope-based. Papers that are technically sound but don't meet the "changes practice" threshold are cut quickly with a brief explanation.

Review timeline

JCO peer review is substantive but moves faster than nature portfolio journals on comparable manuscript types. Clinical trial results are often prioritized for rapid review given their practice implications.

JCO vs. Lancet Oncology: how to choose

For trials with US-focused patient populations and ASCO community relevance, JCO is the natural primary target. For trials with international recruitment or explicit global health framing, Lancet Oncology may be a stronger fit.

APC and open access

JCO is a subscription journal. Open access is available through an APC of approximately $3,500-$4,000 USD for immediate open access, or papers become freely available after 12 months. Many institutions have ASCO or Silverchair agreements.

Practical submission checklist

• [ ] Primary endpoint has direct clinical practice implications for oncology
• [ ] Study design is appropriate: RCT, large prospective cohort, or validated retrospective with strong controls
• [ ] CONSORT (for RCTs) or STROBE (for cohorts) checklist completed
• [ ] Trial registration documented (ClinicalTrials.gov or equivalent) for any interventional study
• [ ] Subgroup analyses pre-specified vs. exploratory clearly distinguished
• [ ] Statistical analysis plan described
• [ ] Patient population representative of the target practice population
• [ ] Cover letter explicitly states what practice change the study supports
• [ ] Competing interests declared (particularly industry funding in oncology)
• [ ] Data sharing statement completed

Sources and further reading

Impact factor data from Clarivate Journal Citation Reports (released June 2025). For submission guidelines, see the JCO author instructions.

See our full Journal of Clinical Oncology journal guide for editorial scope and submission tips. For manuscript preparation, see our avoid desk rejection service.

• Lancet Oncology impact factor guide: IF 35.9, the other top clinical oncology journal
• JAMA Oncology impact factor guide: IF 20.1, the third major clinical oncology journal
• Nature Medicine impact factor guide: IF 50.0, for translational oncology
• How to avoid desk rejection: patterns that get clinical papers cut before review

How JCO's IF Has Trended

JCO's IF has been stable in the 41-45 range across recent years. It didn't experience the COVID-spike that temporarily inflated some general journals, which makes the 2024 number a reliable baseline for career evaluation purposes.

How JCO Compares to Peer Oncology Journals

For US-based clinical oncology researchers, JCO is the primary target for high-impact clinical work. Lancet Oncology and Annals of Oncology have higher IFs but are more accessible for European researchers and international trial data. JAMA Oncology is a strong alternative for oncology work with a cleaner public health or population-level angle.

What JCO Publishes (and What It Doesn't)

JCO focuses on clinical and translational oncology. Phase III randomized trials are the core of the journal. Phase II trials are accepted when they're in rare cancers or when the effect size warrants it. Large translational studies , predictive biomarkers, treatment selection factors , are published when they draw on prospective clinical datasets.

What JCO doesn't publish: purely basic science work, animal studies without clear clinical translation, and retrospective studies in common cancers where the question has already been addressed in larger prospective cohorts.

The cover letter at JCO should lead with the clinical practice implication , which patients, which treatment decisions, and what changes based on your findings. Editors read the abstract and cover letter before anything else, and the clinical relevance needs to be clear in the first paragraph.

What an IF of 41.9 Means for Your Career

A JCO publication as first or last author is among the strongest individual publications in clinical oncology. At most academic medical centers in the US, a first-author JCO paper at the assistant professor level carries weight equivalent to a NEJM or JAMA paper in cardiology.

The IF doesn't just affect your hiring prospects , it affects grant applications, medical school rankings, and department evaluation metrics. A consistent record of JCO-level publications is what sustains a clinical research career at major academic centers.

For industry collaborations, JCO publications in the relevant disease area are one of the primary factors that determine whether a clinical investigator gets approached for sponsored trials.

For clinical oncology researchers at major academic medical centers, a first-author JCO paper is among the most important single publications for a career. Grant agencies, promotion committees, and clinical trial sponsors all recognize JCO immediately. The IF of 41.2 is what it's , the more relevant signal is that your work cleared a rigorous peer review process in the field's leading clinical journal.

The Bottom Line

JCO at 41.2 is the journal of record for clinical oncology. If your study is a phase III randomized trial or a guideline-changing observational study, it belongs in JCO. If it's early-phase or mechanistic, the IF doesn't matter , the fit isn't there. A diagnostic assessment helps you make that call clearly.

See also

• Lancet Oncology Impact Factor 2026
• Cancer Cell Review Time
• JAMA Oncology vs JCO